AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Run by Novo Nordisk A/S · NCT07400107 · Data updated 2026-11-12
Fully enrolled, still running. This study is not taking new participants. Its registered completion date is 2028-12-19.
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. Participant will receive 2 injections every week: an active medicine and a placebo, both taken as injections under the skin once a week. The placebo is a treatment with no active medicine in it and will be given to all participants. In addition to placebo, participants will receive either of the active medicine NNC0487-0111 (the treatment being tested) or Semaglutide (an approved and commonly prescribed treatment used as comparator). Which…
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 985 (actual) |
| Sponsor | Novo Nordisk A/S Industry-sponsored |
| Drugs / interventions | NNC0487-0111, Semaglutide, Placebo (matched to NNC0487-0111), Placebo (matched to semaglutide) |
| Locations | 122 sites (Argentina, Brazil, Bulgaria, Croatia, Germany, Hungary, India, Mexico and more) |
| Trial ID | NCT07400107 on ClinicalTrials.gov |
Who can join: the full rules
Show full inclusion / exclusion criteria
Key Inclusion Criteria: * Male or female (sex at birth). * Age 18 years or above at the time of signing informed consent. * Diagnosed with type 2 diabetes mellitus ≥ 180 days before screening. * Haemoglobin A1c (HbA1c) 7-10 percentage (%) (53-86 millimole per mole \[mmol/mol\]) (both inclusive) as measured by the central laboratory at screening. * Treatment with lifestyle intervention, and/or 0-3 marketed oral antidiabetic drugs (OAD)s (metformin, α-glucosidase inhibitors (AGI), glinides, sodium-glucose cotransporter 2 inhibitor (SGLT2i), thiazolidinediones, or sulfonylureas (SU) as a single agent or in combination) according to local label. Treatment with oral antidiabetic drugs should be stable (same drug(s), dose and dosing frequency) before screening. Key Exclusion Criteria: * Renal impairment with estimated Glomerular Filtration Rate (eGFR) \< 30 milliliter (mL)/ minute (min)/1.73 meter squared (m\^2) (2021 Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula), at screening. * Participant with diabetic retinopathy or maculopathy who received treatment with retinal photocoagulation, vitrectomy or anti-Vascular Endothelial Growth Factor (anti-VEGF) within 180 days before screening or are expected to require treatment within 180 days after screening. Diabetic retinopathy or maculopathy must be verified by an eye examination performed within 90 days before screening or in the period between screening and randomization. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination. * Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question 8. * Recurrent severe hypoglycaemic episodes within the last year as judged by the investigator. * Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment), or amylin analogues before screening.
Where it's running
-
Encore Medical Research LLC
Hollywood, Florida, United States -
Optimal Research Sites
Orange City, Florida, United States -
Encore Medical Research of Weston
Weston, Florida, United States -
Endocrine Research Solutions, Inc
Roswell, Georgia, United States -
Elite Clinical Trials
Blackfoot, Idaho, United States -
Endo And Metab Cons
Rockville, Maryland, United States
Show 44 more locations
-
Arcturus Healthcare, PLC.
Troy, Michigan, United States -
Velocity Clin Res, Dallas
Dallas, Texas, United States -
Consano Clinical Research, LLC
Shavano Park, Texas, United States -
Selma Medical Associates
Winchester, Virginia, United States -
Centro de Investigaciones Metabólicas
Capital Federal, Buenos Aires, Argentina -
Centro Médico CIMEL
Lanús Este, Buenos Aires, Argentina -
Centro Médico Privado San Vicente Diabetes
Córdoba, Argentina -
Núcleo de Pesquisa Clínica do Rio Grande do Sul Ltda.
Porto Alegre, Rio Grande do Sul, Brazil -
i9 Pesquisas Clínicas
Campinas, São Paulo, Brazil -
CPQuali Pesquisa Clínica Ltda
São Paulo, São Paulo, Brazil -
BR Trials - Ensaios Clínicos e Consultoria Ltda.
São Paulo, São Paulo, Brazil -
Dr. Tatyana Metalova - AIPSMCE EOOD
Gotse Delchev, Bulgaria -
Medical centre Zdrave 1 OOD
Kozloduy, Bulgaria -
UMHAT Pulmed OOD - Pazardzhik, Department of Internal Diseases
Pazardzhik, Bulgaria -
MHAT Heart and Brain EAD - Pleven, Endocrinology and Metabolic Diseases
Pleven, Bulgaria -
DCC I- Pleven EOOD Endocrinology
Pleven, Bulgaria -
MHAT Knyaginya Klementina - Sofia EAD
Sofia, Bulgaria -
MHAT Sveta Sofia EOOD, Department of Endocrinology and Metabolic diseases
Sofia, Bulgaria -
Acibadem City Clinic UMHAT Tokuda EAD, Endocrinology
Sofia, Bulgaria -
USHATE Akad. Ivan Penchev EAD, Second Clinic of Endocrinology
Sofia, Bulgaria -
Medical Institute of Ministry of interior
Sofia, Bulgaria -
Medical Centre - Clinic Nova EOOD
Varna, Bulgaria -
Poliklinika Medikol Zagreb
Grad Zagreb, Croatia -
Opca bolnica Karlovac
Karlovac, Croatia -
Specijalna Bolnica za medicinsku rehabilitaciju Krapinske Toplice_Endocrinology
Krapinske Toplice, Croatia -
Poliklinika SLAVONIJA OSIJEK
Osijek, Croatia -
Clinical Hospital Centre Rijeka_Endocrinology
Rijeka, Croatia -
General Hospital Dr. Josip Bencevic_Diabetic department
Slavonski Brod, Croatia -
Opca bolnica Varazdin_Endocrinology
Varaždin, Croatia -
Poliklinika Solmed
Zagreb, Croatia -
Herz- und Diabeteszentrum NRW - Bad Oeynhausen
Bad Oeynhausen, Germany -
Zentrum für klinische Studien Südbrandenburg GmbH
Elsterwerda, Germany -
Praxis am Markt Dr. Becker
Essen, Germany -
MVZ im Altstadt-Carree Fulda GmbH - Zentrum für klinische Studien
Fulda, Germany -
Diabetes-Zentrum-Wilhelmsburg GbR
Hamburg, Germany -
Diabetologische Gemeinschaftspraxis Dr. Staudenmeyer und Dr. Schiwietz
Lingen, Germany -
SMO.MD GmbH - Zentrum für klinische Studien
Magdeburg, Germany -
Institut für Diabetesforschung Osnabrück
Osnabrück, Germany -
ceda - Centrum für Diabetologie und Allgemeinmedizin Pohlheim
Pohlheim, Germany -
Forschungszentrum Ruhr KliFoCenter GmbH, Kahrmann
Witten, Germany -
Békés Vármegyei Központi Kórház
Gyula, Bekes County, Hungary -
Debreceni Egyetem
Debrecen, Hajdú-Bihar, Hungary -
Komáromi Selye János Kórház
Komárom, Komárom-Esztergom, Hungary -
Óbudai Egészségügyi Centrum
Budapest, Pest County, Hungary
+72 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Principal investigator: Clinical Transparency (dept. 2834) — Novo Nordisk A/S
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.